Figure 6.

The optimised protocol improves the potency of doxorubicin-loaded EVs (A) Recovery of EVs when loading in different conditions, regulated by voltage (V), capacitance (µF), and electroporation buffer. Measured by NTA (output/input). The conditions are further described in Table 4, and the buffers are noted as B2, B3, and B8 and are described in further detail in Table 1. (B) Relative cell viability after 48h incubation with the different treatments. The significance is compared to 1 µM doxorubicin control. There was also a significant difference between all modes and EV-NO-DOX at 1E10 Evs, and for all modes except mode 6 at 1E9 and 1E8 EVs. (C) µM doxorubicin in the final sample and effective loading when loading using different conditions regulated by voltage (V), capacitance (µF), and electroporation buffer. (D) Fold increase of potency per µM of effector molecule doxorubicin between different treatments. Significance calculated by ANOVA and is illustrated as follows: ns, p > 0.05; * p < 0.05; **** p < 0.0001.